N-(3-Methoxybenzyl)oleamideCompetitive mGlu receptor antagonist CAS# 883715-21-7 |
- Cevimeline
Catalog No.:BCC1470
CAS No.:107233-08-9
- Tolterodine tartrate
Catalog No.:BCC4586
CAS No.:124937-52-6
- Darifenacin HBr
Catalog No.:BCC4567
CAS No.:133099-07-7
- Solifenacin succinate
Catalog No.:BCC4580
CAS No.:242478-38-2
- Fesoterodine Fumarate
Catalog No.:BCC4584
CAS No.:286930-03-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 883715-21-7 | SDF | Download SDF |
| PubChem ID | 73346080 | Appearance | Oil |
| Formula | C26H43NO2 | M.Wt | 401.6 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble to 5 mM in DMSO and to 100 mM in 1.4 eq. NaOH | ||
| Chemical Name | (Z)-N-[(3-methoxyphenyl)methyl]octadec-9-enamide | ||
| SMILES | CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC(=CC=C1)OC | ||
| Standard InChIKey | ZMKZIKHBSPDWEF-KHPPLWFESA-N | ||
| Standard InChI | InChI=1S/C26H43NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-26(28)27-23-24-19-18-20-25(22-24)29-2/h10-11,18-20,22H,3-9,12-17,21,23H2,1-2H3,(H,27,28)/b11-10- | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Macamides (N-(3-methoxybenzyl)oleamide (MAC 18:1), N-(3-methoxybenzyl)linoleamide (MAC 18:2) and N-(3-methoxybenzyl)linolenamide (MAC 18:3) )achieve their neuroprotective effects by binding to CB1 receptors to protect against Mn-induced toxicity in U-87 MG glioblastoma cells. Additionally these macamides, in a manner similar to the analogous endocannabinoid AEA, interact with other targets such as PPARγ to regulate metabolism and energy homeostasis, cell differentiation and inflammation. |
| Targets | PPARγ |
| In vitro | Neuroprotective activity of macamides on manganese-induced mitochondrial disruption in U-87 MG glioblastoma cells.[Reference: WebLink]Toxicol Appl Pharmacol, 2018, 340:67-76.
Macamides are a distinct class of secondary metabolites, benzylamides of long chain fatty acids, which were isolated from the Peruvian plant Lepidium meyenii (Maca). As structural analogues of the endocannabinoid anandamide (AEA), they have demonstrated neuroprotective effects in vitro and in vivo. The purpose of this study was to demonstrate the neuroprotective activity of the macamides: N-(3-Methoxybenzyl)oleamide (MAC 18:1), N-(3-methoxybenzyl)linoleamide (MAC 18:2) and N-(3-methoxybenzyl)linolenamide (MAC 18:3) in a neurotoxic environment caused by exposure of U-87 MG glioblastoma cells to manganese chloride (MnCl2). The neuroprotective effects of these macamides were reversed by the CB1 antagonist AM251. |
N-(3-Methoxybenzyl)oleamide Dilution Calculator
N-(3-Methoxybenzyl)oleamide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.49 mL | 12.4502 mL | 24.9004 mL | 49.8008 mL | 62.251 mL |
| 5 mM | 0.498 mL | 2.49 mL | 4.9801 mL | 9.9602 mL | 12.4502 mL |
| 10 mM | 0.249 mL | 1.245 mL | 2.49 mL | 4.9801 mL | 6.2251 mL |
| 50 mM | 0.0498 mL | 0.249 mL | 0.498 mL | 0.996 mL | 1.245 mL |
| 100 mM | 0.0249 mL | 0.1245 mL | 0.249 mL | 0.498 mL | 0.6225 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-DAMP
Catalog No.:BCC6661
CAS No.:1952-15-4
- Dihydrosenkyunolide C
Catalog No.:BCC8942
CAS No.:195142-72-4
- 4-Hydroxycinnamamide
Catalog No.:BCN1188
CAS No.:194940-15-3
- Daphnetin 7-methyl ether
Catalog No.:BCN2734
CAS No.:19492-03-6
- ACPT-I
Catalog No.:BCC5702
CAS No.:194918-76-8
- Ginsenoside Rs3
Catalog No.:BCN3716
CAS No.:194861-70-6
- Jujuboside D
Catalog No.:BCN4951
CAS No.:194851-84-8
- Dracoflavan C2
Catalog No.:BCN3586
CAS No.:194794-50-8
- Dracoflavan C1
Catalog No.:BCN3587
CAS No.:194794-49-5
- Dracoflavan B2
Catalog No.:BCN3590
CAS No.:194794-47-3
- Dracoflavan B1
Catalog No.:BCN3589
CAS No.:194794-44-0
- Taxuspine X
Catalog No.:BCN6936
CAS No.:194782-02-0
- GLP-2 (rat)
Catalog No.:BCC5892
CAS No.:195262-56-7
- Tiopronin (Thiola)
Catalog No.:BCC3870
CAS No.:1953-02-2
- Galantamine hydrobromide
Catalog No.:BCN2869
CAS No.:1953-04-4
- Alphitolic acid
Catalog No.:BCN1189
CAS No.:19533-92-7
- JAK2 Inhibitor V, Z3
Catalog No.:BCC1667
CAS No.:195371-52-9
- Bay 11-7821(BAY 11-7082)
Catalog No.:BCC2244
CAS No.:19542-67-7
- Wortmannin
Catalog No.:BCC3874
CAS No.:19545-26-7
- Chiirirhamnin
Catalog No.:BCN3179
CAS No.:195450-50-1
- AP1903
Catalog No.:BCC5361
CAS No.:195514-63-7
- Piromidic Acid
Catalog No.:BCC3840
CAS No.:19562-30-2
- Methyl 4-O-feruloylquinate
Catalog No.:BCC9041
CAS No.:195723-10-5
- 2,16,19-Kauranetriol 2-O-beta-D-allopyranoside
Catalog No.:BCN1510
CAS No.:195723-38-7
Neuroprotective activity of macamides on manganese-induced mitochondrial disruption in U-87 MG glioblastoma cells.[Pubmed:29288688]
Toxicol Appl Pharmacol. 2018 Feb 1;340:67-76.
Macamides are a distinct class of secondary metabolites, benzylamides of long chain fatty acids, which were isolated from the Peruvian plant Lepidium meyenii (Maca). As structural analogues of the endocannabinoid anandamide (AEA), they have demonstrated neuroprotective effects in vitro and in vivo. The purpose of this study was to demonstrate the neuroprotective activity of the macamides: N-(3-Methoxybenzyl)oleamide (MAC 18:1), N-(3-methoxybenzyl)linoleamide (MAC 18:2) and N-(3-methoxybenzyl)linolenamide (MAC 18:3) in a neurotoxic environment caused by exposure of U-87 MG glioblastoma cells to manganese chloride (MnCl2). The neuroprotective effects of these macamides were reversed by the CB1 antagonist AM251. The mechanism by which manganese (Mn) induces cell damage was investigated by studying its effects on mitochondria. Reactive oxygen species (ROS) increase intracellular calcium and enhance the opening of mitochondrial permeability transition pores (MPTP), which leads to decreased mitochondrial membrane potential (MMP), to disruption of mitochondria and to neuron death in neurodegenerative disorders. In this study, MnCl2 at 50muM was responsible for mitochondrial disruption, which was attenuated by all three of the macamides tested. Human peroxisome proliferator-activated receptor gamma (PPARgamma) has been proposed to be a cannabinoid target, and PPARgamma has also been demonstrated to mediate some of the longer-term vascular effects of the plant cannabinoid, 9-tetrahydrocannabinol. PPARgamma activation was observed in response to exposures of cells to MAC 18:2 and MAC 18:3. These findings suggest that macamides achieve their neuroprotective effects by binding to CB1 receptors to protect against Mn-induced toxicity in U-87 MG glioblastoma cells. Additionally these macamides, in a manner similar to the analogous endocannabinoid AEA, interact with other targets such as PPARgamma to regulate metabolism and energy homeostasis, cell differentiation and inflammation.
